Skip to search formSkip to main contentSkip to account menu

BMN 673

Known as: BMN-673 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

talazoparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 4675: Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer
Ovarian cancer recurrence has been shown to be associated with increased DNA damage response (DDR) mediated by poly-(ADP)-ribose… 
2016
2016
Abstract 2098: Understanding the synergy between temozolomide and PARP inhibition in Ewing sarcoma
Ewing sarcoma is the fourth most common highly malignant childhood cancer; it is defined by a tumor-specific chromosomal… 
2015
2015
Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer
Ovarian cancer (OC) is initially chemoresponsive but the majority of patients relapse after first line platinum-, taxane-based… 
Review
2015
Review
2015
[Cancer therapy by PARP inhibitors].
Poly(ADP-ribose) polymerases(PARP) synthesize the ADP-ribose polymers onto proteins and play a role in DNA repair. PARP… 
2015
2015
Mechanistic Dissection of PARP 1 Trapping and the Impacton InVivo TolerabilityandEf fi cacyofPARP Inhibitors
Poly(ADP-ribose) polymerases (PARP1, -2, and -3) play important roles in DNA damage repair. As such, a number of PARP inhibitors… 
2015
2015
Abstract 559: Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway
There is a growing appreciation that defects in homologous recombination repair may increase sensitivity of tumors to certain DNA… 
2015
2015
Abstract 2520: Synergistic combination of lurbinectedin and PARP inhibitors in breast cancer tumor cell lines
Lurbinectedin (PM1183) is a new tetrahydroisoquinoline derivative currently evaluated in phase II trials in BRCA1-mutated breast… 
2015
2015
Abstract 1795: Potent anti-tumor activity of talazoparib (BMN673) in combination with radiation for squamous cell carcinoma of the head and neck
Background: Squamous cell carcinoma of the head and neck (SCCHN) is a radiation-sensitive disease. Standard frontline treatment… 
2014
2014
Abstract 2397: Nanoformulations of PARP inhibtors for cancer therapy
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Poly ADP Ribose Polymerase inhibitor… 
2013
2013
Promise for BRCA-defective cancers
A new drug shows promise for patients with triple-negative breast cancer. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)